Preferential spinal cord volume loss in primary progressive multiple sclerosis

Multiple Sclerosis

Spinal cord volume loss: A marker of disease progression in multiple sclerosis

Neurology.

Tsagkas C, Magon S, Gaetano L, Pezold S, Naegelin Y, Amann M, Stippich C, Cattin P, Wuerfel J, Bieri O, Sprenger T, Kappos L, Parmar K

doi: 10.1212/

Multiple Sclerosis

Long-term disability progression in primary progressive multiple sclerosis: a 15-year study

Brain.

Rocca MA, Sormani MP, Rovaris M, Caputo D, Ghezzi A, Montanari E, Bertolotto A, Laroni A, Bergamaschi R, Martinelli V, Comi G, Filippi M

doi: 10.1093/brain/awx250.

Multiple Sclerosis

Serum neurofilament as a predictor of disease worsening and brain and spinal cord atrophy in multiple sclerosis

Brain

Barro C, Benkert P, Disanto G, Tsagkas C, Amann M, Naegelin Y, Leppert D, Gobbi C, Granziera C, Yaldizli Ö, Michalak Z, Wuerfel J, Kappos L, Parmar K, Kuhle J

doi: 10.1093/brain/awy154.

RECOMMENDED

Multiple Sclerosis

Spinal cord involvement in multiple sclerosis and neuromyelitis optica spectrum disorders

Lancet Neurol.

Ciccarelli O, Cohen JA, Reingold SC, Weinshenker BG; International Conference on Spinal Cord Involvement and Imaging in Multiple Sclerosis and Neuromyelitis Optica Spectrum Disorders

doi: 10.1016/S1474-

Multiple Sclerosis

Chronic white matter lesion activity predicts clinical progression in primary progressive multiple sclerosis

Brain.

Elliott C, Belachew S, Wolinsky JS, Hauser SL, Kappos L, Barkhof F, Bernasconi C, Fecker J, Model F, Wei W, Arnold DL

doi: 10.1093/brain/awz212.

Multiple Sclerosis

Evaluation of no evidence of progression or active disease (NEPAD) in patients with primary progressive multiple sclerosis in the ORATORIO trial

Ann Neurol.

Wolinsky JS, Montalban X, Hauser SL, Giovannoni G, Vermersch P, Bernasconi C, Deol-Bhullar G, Garren H, Chin P, Belachew S, Kappos L

doi: 10.1002/ana.25313.

Multiple Sclerosis

Ocrelizumab versus Placebo in Primary Progressive Multiple Sclerosis

N Engl J Med.

Montalban X, Hauser SL, Kappos L, Arnold DL, Bar-Or A, Comi G, de Seze J, Giovannoni G, Hartung HP, Hemmer B, Lublin F, Rammohan KW, Selmaj K, Traboulsee A, Sauter A, Masterman D, Fontoura P, Belachew S, Garren H, Mairon N, Chin P, Wolinsky JS; ORATORIO Clinical Investigators.

doi: 10.1056/NEJMoa1606468.

Multiple Sclerosis

Progressive multiple sclerosis: from pathogenic mechanisms to treatment

Brain.

Correale J, Gaitán MI, Ysrraelit MC, Fiol MP

doi: 10.1093/brain/aww258.

Multiple Sclerosis

Deep gray matter volume loss drives disability worsening in multiple sclerosis

Ann Neurol.

Eshaghi A, Prados F, Brownlee WJ, Altmann DR, Tur C, Cardoso MJ, De Angelis F, van de Pavert SH, Cawley N, De Stefano N, Stromillo ML, Battaglini M, Ruggieri S, Gasperini C, Filippi M, Rocca MA, Rovira A, Sastre-Garriga J, Vrenken H, Leurs CE, Killestein J, Pirpamer L, Enzinger C, Ourselin S, Wheeler-Kingshott CAMG, Chard D, Thompson AJ, Alexander DC, Barkhof F, Ciccarelli O; MAGNIMS study group

doi: 10.1002/ana.25145.

Related content

Spinal cord volume loss: A marker of disease progression in multiple sclerosis

Long-term disability progression in primary progressive multiple sclerosis: a 15-year study

Serum neurofilament as a predictor of disease worsening and brain and spinal cord atrophy in multiple sclerosis

Spinal cord involvement in multiple sclerosis and neuromyelitis optica spectrum disorders

Chronic white matter lesion activity predicts clinical progression in primary progressive multiple sclerosis

Evaluation of no evidence of progression or active disease (NEPAD) in patients with primary progressive multiple sclerosis in the ORATORIO trial

Ocrelizumab versus Placebo in Primary Progressive Multiple Sclerosis

Progressive multiple sclerosis: from pathogenic mechanisms to treatment

Deep gray matter volume loss drives disability worsening in multiple sclerosis